EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-World Treatment Patterns and Outcomes in Hormone Receptor Positive HER2 Negative Early-Stage Breast Cancer in a Private Community Oncology Practice of Brazil

Aline Coelho Gonçalves, Tomas Reinert, Heloisa Mussato Fernandes da Cruz, Matheus Costa E Silva, Max S Mano, Cristiano Augusto Andrade de Resende, Gustavo Bretas, Leandro Jonata de Carvalho Oliveira, Maria Cristina Figueroa, Rafael Duarte Paes, Jorge Alexandre Canedo, Fernanda Christtanini Koyama und 4 weitere

Clinical Breast Cancer · 2025

DOI: 10.1016/j.clbc.2025.07.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Aline Coelho Gonçalves und 15 weiteren Autor:innen. Beteiligte Einrichtung: Oncoclinicas & CO - Medica Scientia Innovation Research (MedSir), São Paulo, Brazil. Electronic address: alinecoelho2@yahoo.com.br. Hauptthemen laut MEDLINE: Breast Neoplasms, Practice Patterns, Physicians', Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aims to assess the disease characteristics, practice patterns and real-world outcomes of patients (pts) with HR positive (+)/HER2 negative (-) early breast cancer (EBC) treated in Brazil's largest network of community oncology practices. METHODS: Retrospective study from the Oncoclínicas&CO real-world database from 2016 to 2021. We assessed risk profile distribution (high-risk [HR], intermediate-risk [IR] or low-risk [LR]) as per recent adjuvant trials in EBC, endocrine and chemotherapy (CT) prescriptions and 3-year invasive disease-free survival (iDFS). RESULTS: In total, 1,786 cases were selected for the study. Median age was 57 years, 566 (32%) were premenopausal, 1,179 (66%) were LR, 351 (20%) IR, and 256 (14%) HR. In postmenopausal pts, aromatase inhibitor (AI) was used by 74% with LR, 79% with IR and 83% with HR. In premenopausal pts, ovarian function suppression (OFS) - combined with tamoxifen or AI - was prescribed to 18% LR pts, 15% IR, and 48% HR. CT was offered to 32%, 38%, and 73% of postmenopausal pts in LR, IR, and HR groups. In premenopausal pts, 55%, 57%, and 78% received CT in LR, IR, and HR groups. The 3-year iDFS was 86% (95% CI, 84%-89%) in LR population, 87% (82%-91%) in IR, and 72% (95% CI, 65%-81%) in HR. CONCLUSIONS: In this large real-world cohort of patients treated in a private setting in Brazil, most pts are diagnosed with low-risk EBC. We found that a significant proportion of premenopausal pts with high-risk EBC were not treated with OFS and did not receive CT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPractice Patterns, Physicians'Antineoplastic Combined Chemotherapy ProtocolsHumansFemaleBrazilMiddle AgedRetrospective StudiesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneAdultAgedChemotherapy, AdjuvantAromatase InhibitorsAntineoplastic Agents, HormonalPrivate PracticeNeoplasm StagingPremenopause

Stichwörter der Autor:innen

Early Stage Breast CancerReal-worldhormone receptor positiveluminal breast cancerprivate setting

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneAromatase InhibitorsAntineoplastic Agents, HormonalERBB2 protein, human

Autor:innen und Institutionen

  • Oncoclinicas & CO - Medica Scientia Innovation Research (MedSir), São Paulo, Brazil. Electronic address: alinecoelho2@yahoo.com.br.
  • Oncoclinicas & CO - Medica Scientia Innovation Research (MedSir), São Paulo, Brazil.
  • Novartis Biociencias S.A., São Paulo, Brazil.

Förderung

  • Novartis

Zitieren

APA

Gonçalves, A. C., Reinert, T., da Cruz, H. M. F., Costa E Silva, M., Mano, M. S., de Resende, C. A. A., Bretas, G., Oliveira, L. J. C., Figueroa, M. C., Paes, R. D., Canedo, J. A., Koyama, F. C., Bueno, C. T., Ferreira, É. C. M. C., Barrios, C., & Dienstmann, R. (2025). Real-World Treatment Patterns and Outcomes in Hormone Receptor Positive HER2 Negative Early-Stage Breast Cancer in a Private Community Oncology Practice of Brazil. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.07.010

Vancouver

Gonçalves AC, Reinert T, da Cruz HMF, Costa E Silva M, Mano MS, de Resende CAA, et al. Real-World Treatment Patterns and Outcomes in Hormone Receptor Positive HER2 Negative Early-Stage Breast Cancer in a Private Community Oncology Practice of Brazil. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2025.07.010

BibTeX
@article{Gonalves2025,
  author = {Gonçalves, Aline Coelho and Reinert, Tomas and da Cruz, Heloisa Mussato Fernandes and Costa E Silva, Matheus and Mano, Max S and de Resende, Cristiano Augusto Andrade and Bretas, Gustavo and Oliveira, Leandro Jonata de Carvalho and Figueroa, Maria Cristina and Paes, Rafael Duarte and Canedo, Jorge Alexandre and Koyama, Fernanda Christtanini and Bueno, Carolina Tosin and Ferreira, Érica Câmara Mattos de Capps and Barrios, Carlos and Dienstmann, Rodrigo},
  title = {Real-World Treatment Patterns and Outcomes in Hormone Receptor Positive HER2 Negative Early-Stage Breast Cancer in a Private Community Oncology Practice of Brazil},
  journal = {Clinical Breast Cancer},
  year = {2025},
  doi = {10.1016/j.clbc.2025.07.010}
}
Kostenlos starten →